J Cancer 2018; 9(1):205-212. doi:10.7150/jca.21414 This issue Cite

Research Paper

Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors

Chang Jiang1,2,3*, Xiuyu Cai1,2,3*, Hongxia Zhang2,3, Xiaojun Xia2,3, Bei Zhang1,2,3, Liangping Xia1,2,3✉

1. VIP Region, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;
2. State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, 510060, R.P. China;
3. Collaborative Innovation Center for Cancer Medicine, Guangzhou, Guangdong, 510060, R.P. China.
* contributed equally to this paper

Citation:
Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L. Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. J Cancer 2018; 9(1):205-212. doi:10.7150/jca.21414. https://www.jcancer.org/v09p0205.htm
Other styles

File import instruction

Abstract

Background: Blockade of programmed death 1 (PD-1), an inhibitory T lymphocyte receptor, is associated with immune system enhancement and tumor remission in various tumors. We assessed the anti-tumor activity and immune correlates of cancer patients treated with an anti-PD-1 antibody.

Patients and Methods: Twelve patients with advanced metastatic tumors were treated with anti-PD-1 antibody. Responses were assessed after a 12-week treatment regimen. Biochemical and immunological indexes were measured before each cycle.

Results: Among the 12 patients, 3 patients showed partial response while 6 patients had stable disease (objective response rate: 3/12, 25%; disease control rate: 9/12, 75%). During immunotherapy, the proportion of circulating CD3+ T lymphocytes remained stable, with decreasing trends of CD3+CD4+ T helper cell and increase in CD3+CD8+ T memory cells, in patients with stable disease. Additionally, an increase in serum lactate dehydrogenase levels seemed to correlate with tumor progression.

Conclusions: An anti-PD-1 antibody produced objective responses in approximately 25% patients with various solid tumors, demonstrating that it could improve the immune system in vivo.

Keywords: programmed death 1 antibody, refractory solid tumors, clinical activity, lymphocyte.


Citation styles

APA
Jiang, C., Cai, X., Zhang, H., Xia, X., Zhang, B., Xia, L. (2018). Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. Journal of Cancer, 9(1), 205-212. https://doi.org/10.7150/jca.21414.

ACS
Jiang, C.; Cai, X.; Zhang, H.; Xia, X.; Zhang, B.; Xia, L. Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. J. Cancer 2018, 9 (1), 205-212. DOI: 10.7150/jca.21414.

NLM
Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L. Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. J Cancer 2018; 9(1):205-212. doi:10.7150/jca.21414. https://www.jcancer.org/v09p0205.htm

CSE
Jiang C, Cai X, Zhang H, Xia X, Zhang B, Xia L. 2018. Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. J Cancer. 9(1):205-212.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.